Introduction
============

Invasive fungal infections are a major cause of mortality from infection in immunocompromised patients with hematological malignancies, hematopoietic stem cell transplantation (HSCT), and solid organ transplantation (SOT) (De Pauw et al 1999; [@b57]; [@b58]). The introduction of fluconazole prophylaxis in such patients has led to a shift in the epidemiology of fungal infections with a dramatic reduction of the incidence of candidiasis ([@b4]; [@b11]; [@b52]). By contrast, the incidence of mould infections such as aspergillosis and other non-aspergillar fungal infections has increased significantly ([@b52]; [@b85]). Among immunocompromised patients, invasive fusariosis is the second most common cause of mould infections after aspergillosis with an increasing incidence ([@b11]; [@b57]; [@b59]).

*Fusarium* spp. are plant pathogens and soil saprophytes that cause a broad spectrum of infections in humans, including superficial (keratitis, onychomycosis), locally invasive, and disseminated infection. Disseminated fusariosis occurs almost exclusively in immunocompromised individuals ([@b56]; Dignani et al 2004). Recently, Nucci et al reported the clinical characteristics and prognostic factors of 61 patients with fusariosis after HSCT (54 allogeneic HSCT, 7 autologous HSCT). The reported incidence of fusariosis ranged from 5 infections per 1000 HSCTs in human leucocyte antigen (HLA) matched related transplantations to 20 infections per 1000 HSCTs in HLA mismatched transplantations. The survival rate was 13%, with a median onset of 13 days from the diagnosis, and the single prognostic factor for death by multivariate analysis was persistent neutropenia ([@b59]). The incidence of invasive fungal infections is also increasing in SOT ranging between 5% and 20% ([@b49]), probably due to the use of more intense immunosuppression regimens to reduce acute allograft rejection. Between 1996 and 2007, 10 cases of fusariosis in patients who underwent SOT were reported in literature. Nine of them were localized whereas one patient experienced disseminated fusariosis. The infection resolved in 9 of these patients. None died from fusariosis ([@b86]; Heinz et al 1996; Arney et al 1997; Girardi et al 1999; [@b48]; [@b74]; [@b14]; Garbino et al 2004; Lodato et al 2005). Part of these data are presented in [Table 1](#tbl1){ref-type="table"}.

###### 

Cases of fusariosis found by a computerized search of MEDLINE and published from January 2000 to April 2007

  Article, year (Reference)   No.   Type                Pattern           Drug                                              Disease    Setting   Outcome with respect to the last drug
  --------------------------- ----- ------------------- ----------------- ------------------------------------------------- ---------- --------- ---------------------------------------
  [@b48]                      1     not spec.           \-                ABLC                                              \-         SOT       resolved
  [@b54]                      11    not spec.           1 cutaneous       \-                                                Diabetes   \-        \-
                                                        1 cutaneous       \-                                                Diabetes   \-        \-
                                                        1 cutaneous       \-                                                Diabetes   \-        \-
                                                        1 cutaneous       AmB-L                                             NHL        CTH       resolved
                                                        1 pneumonia       \-                                                NHL        CTH       \-
                                                        1 pneumonia       AMBD                                              ALL        CTH       resolved
                                                        1 disseminated    AMBD                                              HM         CTH       died
                                                        1 disseminated    AMBD                                              HM         CTH       died
                                                        1 disseminated    AmB-L                                             HM         CTH       died
                                                        1 disseminated    AMBD, AmB-L                                       HM         CTH       died
                                                        1 disseminated    AMBD, AmB-L                                       HM         CTH       died
  [@b71]                      1     *solani*            keratitis         Fluco,Itra,**Vorico(iv, oral)**                   \-         \-        resolved
  [@b8]                       1     *dimerum*           disseminated      AmB-L                                             ALL        CHT       died
  [@b62]                      1     *oxysporum*         cutaneous         Itra, Fluco                                       \-         \-        improvement
  [@b74]                      1     not spec.           soft tissue       ABLC                                              Amyl       SOT       resolved
  [@b10]                      35    *solani,*           20 disseminated   Fluco 8                                           Cancer     8 BMT     \-
                                    *moniliforme,*      15 localized      Itra 1                                                                 
                                    *oxysporum,*                          AMBD, AmB-L 8                                                          
                                    *proliferatum,*                       Other 18                                                               
                                    *dimerum*                                                                                                    
  [@b79]                      1     *solani*            endophthalmitis   AMBD + Keto, Posa                                 \-         CL        resolved
  [@b6]                       1     not spec.           fungemia          AmB-L, Caspo                                      ALL        CHT       resolved
  [@b14]                      1     *solani*            cutaneous         Itra                                              AS         SOT       improvement
  [@b15]                      1     not spec.           disseminated      AMBD, AmB-L, **Vorico(iv, oral)**                 AML        CHT       resolved
  [@b41]                      1     not spec.           disseminated      AMBD                                              HM         BMT       resolved
  [@b63]                      11    not spec.           disseminated      **Vorico(iv, oral)**                              HM         CTH+BMT   45% resp.
  [@b72]                      1     *oxysporum*         disseminated      AmB-L + **Vorico(iv, oral)**                      SAA        \-        resolved
  [@b84]                      1     *solani*            disseminated      ABCL, Itra, AmB-L,                                AML        CTH       resolved
                                                                          **Vorico(iv, oral)**                                                   
  Garbino et al 2004          1     not spec.           peritonitis       **Vorico(iv)**                                    Diabetes   SOT       resolved
  [@b9]                       1     *dimerum*           disseminated      AmB-L, **Vorico(iv, oral)**                       SAA        BMT       resolved
  [@b30]                      1     not spec.           cutaneous         AmB-L, **Vorico**                                 FES        PDN       resolved
  [@b31]                      1     *solani*            disseminated      AmB-L + **Vorico(iv, oral)**                      AML        CTH       improved
  [@b32]                      1     *solanii*           disseminated      AMBD                                              NHL        BMT       died
  [@b35]                      1     *proliferatum*      pneumonia         Posa                                              \-         SOT       resolved
  [@b38]                      4     not spec.           disseminated      AmB-L                                             AML        CTH       resolved
                                    *verticillioides*   disseminated      AMBD, AmB-L                                       CLL        CTH       resolved
                                    *verticillioides*   disseminated      AmB-L                                             AML        CTH       resolved
                                    *solani*            disseminated      AmB-L                                             NHL        CTH       died
  [@b42]                      2     *solani*            disseminated      AmB-L                                             ALL        BMT       died
                                    not spec.           disseminated      \-                                                AML        BMT       died
  [@b68]                      1     *solani*            corneal abscess   AMBD, **Vorico(iv + topical, oral)**              Abrasion   \-        resolved
  [@b5]                       1     *solani*            cutaneous         Ketoconazole (oral)                               Diabetes   \-        resolved
  [@b16]                      1     not spec.           disseminated      AmB-L, Vorico (oral), AmB-L                       ALL        CTH       died
  [@b21]                      1     *moniliforme*       endophthalmitis   AMBD(topical), **Vorico(oral)**                   Catarct    \-        resolved
  Lodato et al 2005           1     *solani*            liver abscesses   ABLC                                              CD         SOT       resolved
  [@b46]                      3     *solani*            keratitis         Netamycin(ed)                                     \-         \-        resolved
                                    *solani*            keratitis         Netamycin(ed) + Keto(oral)                        \-         \-        resolved
                                    *solani*            keratitis         Netamycin(ed) + Fluco(oral)                                            resolved
  [@b27]                      1     *oxysporum*         keratitis         **Vorico(topical)**                               \-         \-        not resolve
  [@b28]^8^                   1     *oxysporum*         pneumonia         **Vorico(oral)**                                  \-         \-        resolved
  [@b37]                      1     not spec.           cutaneous         **Vorico(oral)**                                  NHL        \-        resolved
  [@b50]                      1     not spec.           disseminated      **Vorico(iv)**                                    Emph       PDN       \-
  [@b73]                      1     *verticillioides*   disseminated      **Vorico(iv, oral)**                              ST         CTH       resolved
  [@b76]                      1     *solani*            disseminated      AmB-L                                             ALL        CTH       resolved
  [@b80]                      1     *solani*            disseminated      AmB-L + **Vorico(iv, oral)**                      AML        BMT       resolved
  [@b12]                      3     not spec.           keratitis         **Vorico(topical)**                               \-         \-        resolved
                                    not spec.           keratitis         **Vorico(orlal + topical)**                       \-         \-        resolved
                                    not spec.           keratitis         **Vorico(oral + topical)**                        \-         \-        not resolved
  [@b83]                      3     not spec.           endolphalmitis    AMBD(topical), **Vorico(iv)**, Posa               \-         CL        resolved
                                    not spec.           keratitis         AMBD(topical), **Vorico(topical + oral)**, Posa   \-         \-        resolved
                                    not spec.           endolphalmitis    **Vorico(topical + iv, oral)**, Posa              \-         CL        resolved

**Abbreviations:** ABLC, amphotericin B lipid complex; AmB-L, liposomal amphotericin B; AMBD, amphotericin B deoxycholate; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Amyl, amyloidosis; AS, Alport syndrome; BMT, allogeneic bone marrow transplantation; Caspo, caspofungin; CD, Caroli's disease; CHT, chemotherapy; CL, contact lens; ed, eye drops; Emph, emphysema; FES, Fisher-Evans syndrome; Fluco, fluconazole; HD, Hodgkin disease; HM, hematological malignancies; Itra, itraconazole; Keto, ketoconazole; PDN, steroids; Posa, posaconazole; SOT, solid organ transplant; ST, solid tumor; Vorico, voriconazole.

The incidence of fusariosis and its mortality rate are significantly higher in patients with hematological malignancies and in those with allogeneic HSCT due to more intense immunosuppression and profound and prolonged neutropenia. The genus *Fusarium* comprises a large number of species (more than 20) and the most common human pathogen is *Fusarium solani* isolated in approximately half of the reported infections. The remaining cases of human fusariosis are caused by *Fusarium oxysporum*, *Fusarium moniliforme*, and *Fusarium verticillioides*, each of which account for 10%--14% of all infections. Considering the increasing incidence of *Fusarium* spp. infections, an increased virulence of these species cannot be excluded ([@b55]; [@b58]).

*Fusarium* spp. manifest an inherent resistance to a multitude of antifungal agents, making the treatment of fusariosis a challenging task especially in severely immunosupressed individuals with hematological malignancies or transplant recipients. In this patient population fusariosis is frequently fatal (Al-Abdely 2003). Despite its equivocal in vitro susceptibility and treatment failures ([@b7]), amphotericin B has remained the drug of choice for the management of disseminated fusariosis ([@b29]). Voriconazole (VRC) is a triazole antifungal agent approved by the FDA in May 2002 for the treatment of fungal infections including aspergillosis, cryptococcosis, scedosporiosis, and fusariosis since in vitro data and clinical evidence indicated activity against *Fusarium* spp. ([@b7]; Espinel-Ingroff et al 2001; [@b61]; [@b15]; [@b34]).

Treatment of fusariosis
=======================

*Fusarium* spp. can cause local and, most importantly, disseminated infections in immunocompromised patients with involvement of multiple organs including the skin ([Figure 1](#fig1){ref-type="fig"}).

![Patient with disseminated fusariosis and skin involvement. The lesions are seen most commonly on extremities and appear as widespread, violaceous (**A**) or erythematous indurated elements (**B**). With the resolution of the infection the skin lesions become darker (**C**) and the lesions disappear (**D**).](tcmr0306-1165-01){#fig1}

For the clinician taking care of patients with hematological malignancies disseminated fungal infections constitute one of the most difficult challenges. In this patient population *Fusarium* spp. is an emerging cause of non-*Aspergillus* mould infection and is associated with high mortality. In 1997 Boutati and Anaissie ([@b11]) described 43 patients with hematological malignancies who developed invasive *Fusarium* spp. infection. Thirteen of these (30%) responded to therapy with amphotericin B deoxycholate (AMBD) or its lipid formulations \[liposomal amphotericin B (AmB-L); amphotericin B lipid complex (ABLC)\]. The majority (70%) of patients died from the infection while a resolution was only seen in patients who ultimately recovered from cytopenia ([@b11]; [@b43]). More recently, 84 cases of *Fusarium* spp. infection in patients with hematological malignancies were reported ([@b58]). Of them, only 21% were alive 90 days after the diagnosis.

Polyenes
========

Current therapy for refractory invasive fungal infections caused by less-common moulds remains inadequate. Since fusariosis may mimic aspergillosis in its clinical manifestations, affected patients were usually treated with amphotericin B, an agent with poor activity *in vitro* against *Fusarium* spp. ([@b66]), whereas evidence of a good *in vivo* activity is reported with ABLC ([@b49]) and AmB-L ([@b38]; [@b76]).

Azoles
======

Itraconazole
------------

Itraconazole was demonstrated to exert negligible activity against *Fusarium* spp. ([@b65]). It has rarely been administered against *Fusarium* spp. infections with unequivocal results. Additionally it has been demonstrated that amphotericin B and VRC are consistantly more effective than itraconazole against *Fusarium* isolates ([@b45]). Itraconazole has seldom been administered for *Fusarium* infections with nonunivocal results ([@b71]; [@b62]; [@b14]; [@b84]).

Voriconazole
------------

VRC is an extended-spectrum, synthetic triazole derivative of fluconazole, whose mechanism of action is inhibition of the cytochrome P450 (CYP)-dependent enzyme 14-α-sterol demethylase, preventing the fungal cell membrane synthesis and causing its disruption ([@b18]; [@b26]; [@b40]; [@b34]; [@b75]).

Intravenous and/or oral VRC is generally well tolerated. Nevertheless, approximately half of all subjects receiving VRC experienced at least one treatment-related adverse event ([@b26]; [@b2]; [@b34]; EMEA summary of product characteristics 2007; [@b75]).

In *Candida* spp. VRC is fungistatic, whereas in filamentous organisms it is fungicidal. VRC shows *in vitro* activity against a variety of yeasts, filamentous fungi and dimorphic moulds. *Candida* spp., *Aspergillus* spp., *Fusarium* spp., and *Scedosporium* spp. are the pathogens against which VRC has been approved for treatment, whereas it has little or no activity against *Zygomycetes*.

Susceptibility of filamentous fungi to VRC was tested by 3 studies ([@b39]; Espinel-Ingroff et al 2001; [@b46]). While Johnson and Espinel-Ingroff obtained minimum inhibitory concentrations (MICs) of between 2 and 8 μg/mL, more recently Linares et al showed that *Fusarium* spp. display greater susceptibility to VRC (MICs 0.25--4 μg/mL) than that reported before ([@b47]). Although animal data suggest a possible correlation between the efficacy of VRC and MIC values, there was no correlation between clinical outcome and MIC values in clinical trials (EMEA 2007).

The efficacy and safety of VRC for the primary treatment of invasive aspergillosis in immunocompromised patients has been described in randomized, non-blind, multinational trials and in observational studies ([@b18]; [@b26]; [@b33]; [@b34]; [@b3]; [@b53]; [@b75]), but also many case reports have shown the efficacy of VRC in the treatment of fusariosis ([Table 1](#tbl1){ref-type="table"}) ([@b71]; [@b15]; [@b63]; [@b72]; [@b84]; [@b9]; Garbino et al 2004; [@b30]; [@b31]; [@b68]; [@b21]; [@b28]; [@b37]; [@b73]; [@b80]; [@b12]). Thirty-four English language case reports were found by a computerized search of MEDLINE from January 2000 to April 2007. We found 20 disseminated fusariosis and 14 localized infections: 10 ocular involvements, 2 cutaneous lesions, 1 pneumonia, 1 peritonitis. Hematological disease was the underlying setting in 18 patients, while solid tumor and chronic emphysema affected one patient each. All the patients with disseminated infection were immunodepressed because of chemotherapy, or HSCT, or steroids administration, as shown in [Table 1](#tbl1){ref-type="table"}. The overall response to VRC for disseminated fusariosis was 63% (12/19 evaluable). Treatment with VRC was initiated in 19 patients with the iv loading dose of 6 mg/kg bid, followed by the maintenance dose of 4 mg/kg bid. The switch to the oral treatment (200 mg bid) was made in 18 patients. Only one patient received the oral formulation of VRC from the start. For localized infections, VRC was administered iv to 5 patients, eventually followed by oral administration for long-term maintenance. Topical VRC preparation could be added. In 6 patients oral voriconazole was administered from the beginning, while 2 patients received only topical formulations. In 3 patients with disseminated fusariosis, combined therapy consisting in voriconazole and AmB-L was administered, while VRC was given as salvage treatment in 4 patients with disseminated fusariosis (data shown in [Table 1](#tbl1){ref-type="table"}).

Recently, Perfect et al reported a multicenter, open-label, clinical study to assess the efficacy and safety of VRC for the treatment of less-common, emerging or refractory invasive fungal infections ([@b63]). Three-hundred and one immunocompromised patients were studied. The drug was administered iv at recommended dosages for at least 3 days, and the median duration of iv treatment was 18 days (range 1--138 days). Thereafter patients could be switched to oral treatment. The median duration of oral administration was 69 days (range 1--326 days). In the study they treated 11 fusariosis, showing 45% of satisfactory global response with respect to the high mortality rate (70%) for disseminated fusariosis treated with other therapies ([@b44]; [@b11]; [@b63]). These results were consistent with data from previous reports focused on the use of VRC in critically ill patients. They confirm its good profile concerning safety and tolerability, with an incidence of treatment-related toxicities, such as visual disturbances and rashes, requiring suspension for 3.5% of patients, but none of the toxicities were severe. Also liver function abnormalities were noted in \>10% of patients, but only 2.4% had their treatment discontinued, confirming previously reported data ([@b69]).

Posaconazole
------------

Posaconazole (PSC) is a potent extended spectrum tiazole that has been shown to be highly active against yeasts and moulds, including *Fusarium* spp. (Espinel-Ingrof et al 2004; [@b82]). Recently, Raad et al described a clinical experience with PSC utilized for refractory fusariosis or for patients intolerant to conventional antifungal therapy in 21 cases, with an overall response of 48%. This result is comparable with those seen with VRC, and prolonged neutropenia was an unfavorable risk factor of non-response (20% in patients who recovered from myelosuppression versus 67% in patients who did not recover) ([@b70]). Moreover, 4 cases of ocular infection and 1 case of pneumonia by *Fusarium* spp. were described, treated and resolved with PSC after failure of treatment with VRC (iv, oral, and topical formulation) and other antifungal drugs ([@b79]; [@b35]; [@b83]).

![Biopsy of nodular skin lesion at the diagnosis (**A**) and after treatment (**B**).](tcmr0306-1165-02){#fig2}

PSC is administered as an oral suspension with food and this could limit its use in critically ill patients.

These results suggest PSC can be considered an appropriate alternative antifungal therapy to amphotericin B formulation, leading to results similar to those once found with VRC.

Echinocandins
=============

*Fusarium* spp. are usually resistant to echinocandins by standard susceptibility testing ([@b78]). Instead, a case of fungemia sustained by *Fusarium* spp. resistant to amphotericin B was resolved with caspofungin at standard doses in a patient with acute myeloid leukemia ([@b6]). A recent murine model disclosed that caspofungin at 1 mg/kg/day improved survival during active fusariosis, despite lack of reduction in fungal burden ([@b78]), suggesting a potential role in the treatment of human fusariosis.

Future perspectives
===================

The in vitro interaction of itraconazole, amphotericin B and VRC with anidulafungin against *Aspergillus* spp. and *Fusarium* spp. was recently evaluated ([@b67]). Anidulafungin belongs to the echinocandins antifungal drugs class. The data showed that all drug combinations suggested indifference against *Fusarium* spp, but not antagonism or synergism. A previous study reported a potential synergistic to additive effect of caspofungin in combination with amphotericin B against *Fusarium* spp. ([@b20]). Also the combination of VRC and micafungin was tested showing a synergistic effect against *Fusarium* spp. ([@b36]), but clinical studies are needed to confirm these data.

Nystatin is classified among the most efficient antifungal agents, widely used since 1950s, but insoluble in water. The in vitro activity of polymeric complexes of nystatin was investigated against growth inhibition and spore germination of *Fusarium oxysporum*. These complexes of nystatin were 3--25 times more active than nystatin against spore germination and were effective inhibitors of mycelial growth ([@b13]). Their use in the clinical setting has not yet been investigated.

Conclusions
===========

Invasive fusariosis is an emerging cause of mould infections in immunocompromised patients, with usually poor prognosis being *Fusarium* spp. resistant to most available antifungal agents ([@b57]). In vitro susceptibility testing may be the only clue in the choice of the appropriate antifungal agent ([@b1]). The only antifungal drugs effective against *Fusarium* spp, as evidenced by their relatively low MICs, are amphotericin B, nystatin, ketoconazole, VRC, and PSC ([@b22]; [@b45]; [@b81]; [@b17]), whereas fluconazole, itraconazole, and the echinocandins are not active alone against *Fusarium* spp. ([@b22]; [@b51]; [@b64]; [@b45]). VRC has a slightly broader spectrum of activity against most moulds, showing very good in vitro activity against *Aspergillus* spp., *Fusarium* spp, *Scedosporium* spp. ([@b19]; [@b45]; [@b47]). Many case reports have demonstrated the efficacy of VRC in the treatment of fusariosis ([@b71]; [@b15]; [@b63]; [@b72]; [@b84]; [@b9]; Garbino et al 2004; Guimerá-MartÍn-Neda et al 2004; Guzman-Cotrilli et al 2004; [@b68]; [@b21]; [@b28]; [@b37]; [@b73]; [@b80]; [@b12]), with a 63% overall response for disseminated fusariosis, while Perfect et al reported a 45% satisfactory global response, with respect to the high mortality rate (70%) for patients treated with other antifungal drugs ([@b63]).

PSC is a new potent extended spectrum tiazole that has been shown to be active against *Fusarium* spp. (Espinel-Ingrof et al 2004; [@b82]; [@b70]). However, no clinical trials have hitherto compared PSC with VRC or addressed the relative use of these two broad spectrum tiazole agents in the management of fusariosis. Polymeric complexes of nystatin have been investigated against *Fusarium oxysporum*, but there have been no published clinical trials.

In conclusion, treatment of emerging invasive fungal infections is a major challenge, with no standardized therapy and high mortality rates. VRC seems to be the most promising antifungal agent for the treatment of disseminated fusariosis in immunocompromised subjects, but more clinical evidence is required.
